Zobrazeno 1 - 10
of 123
pro vyhledávání: '"F, Carpagnano"'
Autor:
DF Bavaro, L Diella, AG Solimando, S Cicco, E Buonamico, C Stasi, M Ciannarella, M Marrone, F Carpagnano, O Resta, GE Carpagnano, VO Palmieri, A Vacca, M Dell’Aera, A Dell’Erba, G Migliore, M Aricò, A Saracino
Publikováno v:
Pathogens and global health. 116(5)
The early administration of anti-SARS-CoV-2 monoclonal antibodies (mAb) could decrease the risk of severe disease and the need of inpatients care. Herein, our clinical experience with Bamlanivimab/Etesevimab for the treatment of early SARS-CoV-2 infe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f512c102022097c7727a35f3428b44af
https://pubmed.ncbi.nlm.nih.gov/35138229
https://pubmed.ncbi.nlm.nih.gov/35138229
Autor:
Quaranta, Vitaliano Nicola1 (AUTHOR) vitalianonicola.quaranta@asl.bari.it, Portacci, Andrea1 (AUTHOR), Montagnolo, Francesca1 (AUTHOR), Dragonieri, Silvano1 (AUTHOR) silvano.dragonieri@uniba.it, Iorillo, Ilaria1 (AUTHOR), Lulaj, Ernesto1 (AUTHOR), Maselli, Leonardo1 (AUTHOR), Buonamico, Enrico1 (AUTHOR), Carpagnano, Giovanna Elisiana1 (AUTHOR)
Publikováno v:
Journal of Clinical Medicine. Nov2024, Vol. 13 Issue 21, p6309. 15p.
Autor:
Nikolic, Valentina N.1 (AUTHOR) valentina@medfak.ni.ac.rs, Popadic, Višeslav2 (AUTHOR), Jankovic, Slobodan M.3 (AUTHOR), Govedarović, Nenad4 (AUTHOR), Vujić, Stevan5 (AUTHOR), Andjelković, Jelica5 (AUTHOR), Stosic, Lazar S.5 (AUTHOR), Stevanović, Nikola Č.5 (AUTHOR), Zdravkovic, Marija2,6 (AUTHOR), Todorovic, Zoran2,7 (AUTHOR)
Publikováno v:
BMC Research Notes. 10/28/2024, Vol. 17 Issue 1, p1-6. 6p.
Autor:
Sancıoğlu Demir, Merve1 sancioglumerve@gmail.com, Kuşcu, Ferit1, Kurtaran, Behice1, Candevir, Aslıhan1, İnal, Ayse Seza1, Kömür, Süheyla1, Taşova, Yeşim1
Publikováno v:
Journal of Infection in Developing Countries. 2024 Supplement, Vol. 18, pS33-S39. 7p.
Autor:
Maneechotesuwan, Kittipong1 (AUTHOR) kittipong.man@mahidol.ac.th, Aggarwal, Bhumika2 (AUTHOR), Garcia, Gabriel3 (AUTHOR), Tan, Daniel4 (AUTHOR), Neffen, Hugo5 (AUTHOR), Javier, Ramon Jason M.6 (AUTHOR), Al-Ahmad, Mona7 (AUTHOR), Khadada, Mousa8,9 (AUTHOR), Quan, Vu Tran Thien10,11 (AUTHOR), Teerapuncharoen, Krittika1 (AUTHOR), Ramos, Mario Soto12,13 (AUTHOR), Levy, Gur14 (AUTHOR), Plank, Maximilian15 (AUTHOR), Phansalkar, Abhay16 (AUTHOR), Gibson, Peter G.17,18 (AUTHOR)
Publikováno v:
Pulmonary Therapy. Sep2024, Vol. 10 Issue 3, p279-295. 17p.
Autor:
S. Mancarella, F. Carpagnano, N. Panza, Domenico Sambiasi, Michele Guida, Nicola Silvestris, M. De Lena, E. Crucitta, Vito Lorusso
Publikováno v:
Annals of Oncology. 13:1862-1867
Background The aim of our study was to determine the maximum tolerated dose of paclitaxel combined with a fixed dose of gemcitabine and vinorelbine in the treatment of non-small-cell lung cancer (NSCLC) and to evaluate in a phase II trial the efficac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::046b983cd6e567ce0adb9d9c66c00417
https://doi.org/10.1093/annonc/mdf308
https://doi.org/10.1093/annonc/mdf308
Autor:
Saikh, Kamal U.1 (AUTHOR) khairulanamindia@gmail.com, Anam, Khairul1 (AUTHOR), Sultana, Halima1 (AUTHOR), Ahmed, Rakin1 (AUTHOR), Kumar, Simran1 (AUTHOR), Srinivasan, Sanjay1 (AUTHOR), Ahmed, Hafiz1 (AUTHOR) ksaikh@glycomantra.com
Publikováno v:
International Journal of Molecular Sciences. Aug2024, Vol. 25 Issue 15, p8421. 20p.
Autor:
Lorusso, M Cisternino, F Carpagnano, M Guida, M Delena, A Latorre, G diRienzo, M. Brandi, R Ricco, Annamaria Catino, S Parisi
Publikováno v:
Scopus-Elsevier
Thirty patients with marginally resectable stage IIIA or stage IIIB NSCLC were treated with cisplatin (80 mg/ m(2)/i.v./dl), ifosfamide (4,000 mg/m(2)/i.v./dl) and vinorelbine (30 mg/m(2)/i.v./dl) plus G-CSF 300 mu g/s.c. on days 7-12 every 14 days f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c3b1bca731ce259851fc9454c1ec411
https://pubmed.ncbi.nlm.nih.gov/21544412
https://pubmed.ncbi.nlm.nih.gov/21544412
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
G, Frasci, N, Panza, P, Comella, G P, Nicolella, M, Natale, L, Manzione, D, Bilancia, R, Cioffi, L, Maiorino, G, De Cataldis, M, Belli, E, Micillo, V, Mascia, B, Massidda, V, Lorusso, M, De Lena, F, Carpagnano, A, Contu, G, Pusceddu, G, Comella
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 17(8)
Because both cisplatin-paclitaxel and cisplatin-gemcitabine combinations are generally considered to be among the most active regimens in non-small-cell lung cancer (NSCLC) patients, this study aimed to determine the maximum-tolerated dose (MTD) of p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b04f84c52a4b0ef5a0bebe8b804ffb97
https://pubmed.ncbi.nlm.nih.gov/10561293
https://pubmed.ncbi.nlm.nih.gov/10561293